New $27 million Evelyn Lauder Founder's Fund will increase BCRF investment in research that focuses on the molecular basis of cancer metastasis
The April 28, 2013 article in The New York Times
(published online on April 25), "Our Feel-Good War on Breast Cancer
," acknowledges the need for more research on the causes and management of metastasis, the lethal aspect of breast cancer. Indeed, The Breast Cancer Research Foundation (BCRF) is focused exclusively on research and directs nearly 90 percent of its expenditures to clinical and translational investigations into the causes and treatment of breast cancer, and another 3 percent to educational efforts in spreading awareness about this research and its impact. Of the
$40 million in grants the Foundation awarded to investigators in 2012, approximately $18 million is invested in studies related to metastasis, therapy resistance, and disease recurrence.
In addition, BCRF recently announced an unprecedented initiative: a broad program with a narrow focus that will enable more researchers to analyze the molecular abnormalities in metastatic breast cancer. Called the Evelyn H. Lauder Founder's Fund, the initiative will dedicate $27 million to advancing understanding of why some cancers spread more quickly than others, as well as why some cancers respond so well to therapies while others do not. The multi-million dollar, global collaborative program will focus on dissecting the molecular basis of metastasis using the full range of modern scientific tools and thereby guide more effective detection, prognostication, management and-ideally-prevention strategies. The elimination of death and suffering from breast cancer will depend on creative science, and BCRF remains dedicated to this mission.
Please keep checking back for updates on this exciting new initiative.